{"id":4638,"date":"2025-04-24T11:28:17","date_gmt":"2025-04-24T02:28:17","guid":{"rendered":"https:\/\/www.nanomrna.co.jp\/en\/?page_id=4638"},"modified":"2025-05-16T12:04:11","modified_gmt":"2025-05-16T03:04:11","slug":"pipeline","status":"publish","type":"page","link":"https:\/\/www.nanomrna.co.jp\/en\/pipeline\/","title":{"rendered":"Pipeline"},"content":{"rendered":"
\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Target Factor<\/th>\nIndication<\/th>\nSeed<\/th>\nPre-Clinical<\/th>\nPhase I<\/th>\n<\/tr>\n

<\/p>\n

TUG1 ASO<\/td>\n<\/tr>\n
GBM<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n
<\/div>\n<\/td>\n
\n
<\/div>\n<\/td>\n
\n
<\/div>\n<\/td>\n<\/tr>\n
Partner: Nagoya University<\/span><\/td>\n<\/td>\n<\/tr>\n

<\/p>\n

RUNX1 mRNA<\/td>\n<\/tr>\n
Osteo arthritis<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n
<\/div>\n<\/td>\n
\n
<\/div>\n<\/td>\n
<\/td>\n<\/tr>\n
PrimRNA*<\/sup>
Partner: Science Tokyo University<\/span><\/td>\n		<\/td>\n<\/tr>\n

<\/p>\n

\uff4dRNA<\/td>\n<\/tr>\n
Ophthalmic<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n
<\/div>\n<\/td>\n
\n
<\/div>\n<\/td>\n
<\/td>\n<\/tr>\n
Partner: Senju<\/span><\/td>\n<\/td>\n<\/tr>\n

<\/p>\n

mRNA<\/td>\n<\/tr>\n
Allergy<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n
<\/div>\n<\/td>\n
\n
<\/div>\n<\/td>\n
<\/td>\n<\/tr>\n
Partner: Kao Corporate<\/span><\/td>\n<\/td>\n<\/tr>\n

<\/p>\n

mRNA<\/td>\n<\/tr>\n
Allergy<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n
<\/div>\n<\/td>\n
<\/td>\n<\/td>\n<\/tr>\n
Partner: Kao Corporate<\/span><\/td>\n<\/td>\n<\/tr>\n

<\/p>\n

TUG1 ASO successor<\/td>\n<\/tr>\n
Solid cancer<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n
<\/div>\n<\/td>\n
<\/td>\n<\/td>\n<\/tr>\n
Partner: Nagoya University<\/span><\/td>\n<\/td>\n<\/tr>\n

<\/p>\n

PRDM14 siRNA successor<\/td>\n<\/tr>\n
Solid cancer<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n
<\/div>\n<\/td>\n
<\/td>\n<\/td>\n<\/tr>\n
Partner: Kanazawa University<\/span><\/td>\n<\/td>\n<\/tr>\n

<\/p>\n

Genome Edition mRNA<\/td>\n<\/tr>\n
Cancer<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n
<\/div>\n<\/td>\n
<\/td>\n<\/td>\n<\/tr>\n
Partner: Undisclosed<\/span><\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

*Subsidiary of NANO MRNA<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Target Factor Indication Seed Pre-Clinical Phase I TUG1 ASO GBM Partner: Nagoya University RUNX1 mRNA Osteo ar […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":21,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/4638"}],"collection":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/comments?post=4638"}],"version-history":[{"count":3,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/4638\/revisions"}],"predecessor-version":[{"id":4657,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/4638\/revisions\/4657"}],"wp:attachment":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/media?parent=4638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}